The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InReflecting a robust operational performance in the biomanufacturing sector, Lonza Group AG reported significant financial results for the first half of 2026. According to reports, the company achieved a 16% growth in sales and a substantial 44% increase in net profit. This performance was primarily driven by higher asset utilization and double-digit growth across key segments, including Biologics and Advanced Synthesis.
Following these strong results, management has raised its 2026 CORE EBITDA margin outlook to a range of 33–34%. While the company maintained its existing sales growth targets, the upward revision in margin guidance signals improved operational efficiency and a stronger outlook for future profitability within its manufacturing operations.
In the markets, the stock 0QNO.L stood at 536.40 USD as of the close on July 22, 2026, having reached a daily high of 554 USD. Investors will be watching for continued execution on these margin targets, while broader market sentiment may be influenced by upcoming regional data, such as the Eurozone CPI release scheduled for July 17, 2026.